© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com
Amicus Therapeutics, Inc. (FOLD) stock surged +0.32%, trading at $9.54 on NASDAQ, up from the previous close of $9.51. The stock opened at $9.50, fluctuating between $9.47 and $9.61 in the recent session.
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data. It also develops AT-GAA, a novel treatment paradigm for Pompe disease; enzyme replacement therapies for Pompe diseases; CLN3, which is in Phase 1/2 clinical study to evaluate the safety and efficacy of a single intrathecal administration of an AAV serotype AT-GTX-502 gene therapy in patients with CLN3; and CDKL5, a gene on the X-chromosome encoding the CDKL5 protein that regulates the expression of essential proteins for normal brain development. The company has collaboration and license agreements with Nationwide Children's Hospital; University of Pennsylvania; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania.
Employees | 500 |
Beta | 0.67 |
Sales or Revenue | $399.36M |
5Y Sales Change% | 1.755% |
Fiscal Year Ends | December |
Sector | Healthcare |
Industry | Biotechnology |
Amicus Therapeutics, Inc. (NASDAQ: FOLD) stock price is $9.54 in the last trading session. During the trading session, FOLD stock reached the peak price of $9.61 while $9.47 was the lowest point it dropped to. The percentage change in FOLD stock occurred in the recent session was 0.32% while the dollar amount for the price change in FOLD stock was $0.03.
The NASDAQ listed FOLD is part of Biotechnology industry that operates in the broader Healthcare sector. Amicus Therapeutics, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Mr. Bradley L. Campbell M.B.A.
Chief Executive Officer, Pres & Director
Ms. Diana Moore
Head of Global Corporation Communications
Mr. John F. Crowley
Executive Chairman
Ms. Daphne E. Quimi CPA, M.B.A.
Chief Financial Officer
Ms. Ellen S. Rosenberg
Chief Legal Officer & Corporation Sec.
Mr. David M. Clark
Chief People Officer
Mr. Patrik S. Florencio
Senior Vice President, Global Chief Compliance & Risk Officer
Dr. Jill Weimer Ph.D.
Chief Science Officer
Andrew Faughnan
Senior Director of Investor Relations
Ms. Samantha Prout
Chief Accounting Officer & Controller
Mr. Patrik S. Florencio Esq.
Global Chief Compliance & Risk Officer
Dr. Jeffrey P. Castelli
Chief Devel. Officer
FOLD's closing price is 8.53% higher than its 52-week low of $8.79 where as its distance from 52-week high of $14.03 is -32%.
Number of FOLD employees currently stands at 500.
Official Website of FOLD is: https://amicusrx.com
FOLD could be contacted at phone 215 921 7600 and can also be accessed through its website. FOLD operates from 3675 Market Street, Philadelphia, PA 19104, United States.
FOLD stock volume for the day was 1.59M shares. The average number of FOLD shares traded daily for last 3 months was 2.45M.
The market value of FOLD currently stands at $2.85B with its latest stock price at $9.54 and 298.81M of its shares outstanding.